June 2 (Reuters) – Cancer test maker Grail Inc (GRAL.O) said on Friday that its telemedicine vendor erroneously sent letters to about 400 patients suggesting they may have developed cancer.
Grail’s flagship cancer detection blood test Galleri is designed to detect more than 50 types of cancer before symptoms appear.
The company, owned by Illumina Inc (ILMN.O), said the letters were mistakenly sent by PWNHealth due to a software issue and that it “was in no way related to or caused by an incorrect Galleri test result”.